Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients

被引:58
作者
Hahn, T
Rondeau, C
Shaukat, A
Jupudy, V
Miller, A
Alam, AR
Baer, MR
Bambach, B
Bernstein, Z
Chanan-Khan, AA
Czuczman, MS
Slack, J
Wetzler, M
Mookerjee, BK
Silva, J
McCarthy, PL
机构
[1] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA
[2] SUNY Buffalo, Sch Med & Biomed Sci, Dept Med, Buffalo, NY 14260 USA
[3] Dept Pediat Oncol, Buffalo, NY USA
[4] Roswell Pk Canc Inst, Dept Radiat Oncol, Buffalo, NY 14263 USA
关键词
renal failure; stem cell transplantations; toxicity;
D O I
10.1038/sj.bmt.1704144
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
We examined the incidence, risk factors and associated mortality of acute renal failure requiring dialysis (Renal Bearman Grade [BG] 3) in a 3-year cohort of 97 consecutive allogeneic blood and marrow transplantation (alloBMT) patients. In all, 20 (21%) developed Renal BG3 (all died by day + 132) and 77 (79%) developed renal insufficiency (Renal BG1-2). Renal BG3 was a contributing or primary cause of death in 18 (90%) patients who continued to require dialysis at time of death. The two Renal BG3 patients whose deaths were not related to renal failure died on day + 103 of hemorrhage and day + 132 of underlying disease. By univariate analysis, age, unrelated donor, veno-occlusive disease (VOD) and grade III-IV acute graft-versus-host disease with hepatic involvement were significantly associated with Renal BG3. The multivariate model of time to Renal BG3 determined only a prior diagnosis of severe acute GVHD (RR = 4.1, 95% CI 1.6-10.3, P = 0.003) and VOD (RR = 9.1, 95% CI 3.5-23.7, P<0.001) as significant independent predictors. Renal BG3 is generally considered a conditioning regimen-related toxicity. This study demonstrates that Renal BG3 is most commonly a complication of hepatic co-morbidities after allogeneic blood and marrow transplantation and identifies patients with a very poor prognosis.
引用
收藏
页码:405 / 410
页数:6
相关论文
共 26 条
[1]  
Alam A, 1997, BLOOD, V90, P449
[2]  
Alidina A, 1999, Biol Blood Marrow Transplant, V5, P322, DOI 10.1016/S1083-8791(99)70008-X
[3]   CYCLOSPORIN A ASSOCIATED NEPHROTOXICITY IN THE 1ST 100 DAYS AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION - 3 DISTINCT SYNDROMES [J].
ATKINSON, K ;
BIGGS, JC ;
HAYES, J ;
RALSTON, M ;
DODDS, AJ ;
CONCANNON, AJ ;
NAIDOO, D .
BRITISH JOURNAL OF HAEMATOLOGY, 1983, 54 (01) :59-67
[4]   REGIMEN-RELATED TOXICITY IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].
BEARMAN, SI ;
APPELBAUM, FR ;
BUCKNER, CD ;
PETERSEN, FB ;
FISHER, LD ;
CLIFT, RA ;
THOMAS, ED .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) :1562-1568
[5]  
BEARMAN SI, 1994, BONE MARROW TRANSPL, V13, P31
[6]   HIGH-DOSE ETOPOSIDE, CYCLOPHOSPHAMIDE, AND TOTAL-BODY IRRADIATION WITH ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID-LEUKEMIA IN UNTREATED FIRST RELAPSE - A STUDY BY THE NORTH-AMERICAN MARROW TRANSPLANT GROUP [J].
BROWN, RA ;
WOLFF, SN ;
FAY, JW ;
PINEIRO, L ;
COLLINS, RH ;
LYNCH, JP ;
STEVENS, D ;
GREER, J ;
HERZIG, RH ;
HERZIG, GP .
BLOOD, 1995, 85 (05) :1391-1395
[7]   CYCLOSPORINE, METHOTREXATE, AND PREDNISONE COMPARED WITH CYCLOSPORINE AND PREDNISONE FOR PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE [J].
CHAO, NJ ;
SCHMIDT, GM ;
NILAND, JC ;
AMYLON, MD ;
DAGIS, AC ;
LONG, GD ;
NADEMANEE, AP ;
NEGRIN, RS ;
ODONNELL, MR ;
PARKER, PM ;
SMITH, EP ;
SNYDER, DS ;
STEIN, AS ;
WONG, RM ;
BLUME, KG ;
FORMAN, SJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (17) :1225-1230
[8]   LIMITED TOLERANCE OF INTENSIFIED CONDITIONING REGIMENS IN CHILDREN RECEIVING METHOTREXATE CYCLOSPORINE-A FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS [J].
EMMINGER, W ;
EMMINGERSCHMIDMEIER, W ;
PETERS, C ;
HAWLICZEK, R ;
HOCKER, P ;
GADNER, H .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1992, 9 (01) :1-9
[9]   Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation [J].
Giralt, S ;
Thall, PF ;
Khouri, I ;
Wang, XM ;
Braunschweig, I ;
Ippolitti, C ;
Claxton, D ;
Donato, M ;
Bruton, J ;
Cohen, A ;
Davis, M ;
Andersson, BS ;
Anderlini, P ;
Gajewski, J ;
Kornblau, S ;
Andreeff, M ;
Przepiorka, D ;
Ueno, NT ;
Molldrem, J ;
Champlin, R .
BLOOD, 2001, 97 (03) :631-637
[10]   CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS [J].
GLUCKSBERG, H ;
STORB, R ;
FEFER, A ;
BUCKNER, CD ;
NEIMAN, PE ;
CLIFT, RA ;
LERNER, KG ;
THOMAS, ED .
TRANSPLANTATION, 1974, 18 (04) :295-304